1/2 @Bloomberg went inside Amgen @deCODE genetics in Iceland to get an exclusive look at how Amgen is using human DNA to shape our distinct approach to obesity research: bloomberg.com/news/videos/20…
$AMGN
In her latest blog, Susan Sweeney, Executive Vice President, Obesity and Related Conditions, explores the idea that obesity treatment is not simply about helping patients get started. It’s about helping them stay on the path to meaningful, long-term progress. Read more: amgen.ly/48ti6TW
As we head into #HLTHUSA and #ObesityWeek, one thing is clear: the future of obesity care will be shaped by the conversations we have and actions we take together.
By bringing together diverse voices, these meetings create opportunities to address the significant burdens that continue to impact millions of people living with obesity.
#SjogrensDisease news: Amgen presented late-breaking Phase 3 results at #ACR26. The study showed improvements in systemic disease activity and symptoms.
🔗 amgen.ly/4BWqWqw
$AMGN
At AHA #ScientificSessions26, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence.
Read the press release: amgen.ly/4BU8qPs
$AMGN
Why do some people develop heart disease while others don’t?
Amgen research leader and AHA Population Research Prize recipient Pradeep Natarajan shares insights in a new Q&A article.
amgen.ly/4iBF5Ra
Amgen reports Q3 2026 earnings: amgen.ly/4iu1ik1
Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve.
Safe Harbor: amgen.ly/4iE0FER
$AMGN
At AHA #ScientificSessions26, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care.
Explore our abstracts ⬇️
Every story is personal. Every voice can help bring our mission into focus. Meet people whose experiences with cancer, cardiovascular disease, rare disease and obesity have shaped their lives and perspectives.
At Amgen, serving patients is our mission. We’re honored to be named to @TIME World’s Best Companies 2026 list: amgen.ly/4ipVlEY
Innovation has deep roots in Massachusetts, and Amgen is proud to have been part of its life sciences community for 25 years. From our research center in Cambridge, our teams continue to push the boundaries of science to advance medicines for patients around the world.
Learn more about our history in Massachusetts: amgen.ly/4iqQtzr






